Obesity in adolescents: a review
The content on the SheMed blog is provided for general informational and educational purposes only
34 Angarita et al 15 found that pretreatment with a clinically relevant (antidiabetic) dose of exenatide (5 g, 0.02 mL) did not alter the cocaine-related behaviors or subjective effects such as euphoria and wanting cocaine in people with cocaine use disorder compared to placebo (saline 0.02 mL)
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
This particular support stack meets that criteria, while also focusing on key concerns GLP-1 users face

Review the sources used below for this article: This article references information from the KFF (Kaiser Family Foundation) Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford This article references information from the FDA: FDA Approves First Treatment to Reduce Risk of Serious Heart Problems, Specifically in Adults with Obesity or Overweight This article references information from a recent study published in The New England Journal of Medicine : Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity This article references information from the American College of Cardiology: OASIS 4: Significant Weight Loss With Oral Semaglutide Comparable With High-Dose, SC Versions This article references information from Reuters: Lilly will have supply of new weight loss pill for many countries, exec says